KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Equity Ratio (2019 - 2025)

Royalty Pharma's Equity Ratio history spans 7 years, with the latest figure at 0.5 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 12.76% year-over-year to 0.5; the TTM value through Dec 2025 reached 0.5, down 12.76%, while the annual FY2025 figure was 0.5, 12.76% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.5 at Royalty Pharma, roughly flat from 0.5 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.63 in Q2 2021 and bottomed at 0.5 in Q4 2025.
  • The 5-year median for Equity Ratio is 0.58 (2022), against an average of 0.57.
  • The largest annual shift saw Equity Ratio grew 8.66% in 2023 before it fell 12.76% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.59 in 2021, then dropped by 3.17% to 0.57 in 2022, then rose by 8.66% to 0.62 in 2023, then dropped by 7.8% to 0.57 in 2024, then dropped by 12.76% to 0.5 in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Equity Ratio are 0.5 (Q4 2025), 0.5 (Q3 2025), and 0.52 (Q2 2025).